Raja, J;
Nihtyanova, SI;
Murray, CD;
Denton, CP;
Ong, VH;
(2016)
Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Rheumatology
, 55
(1)
pp. 115-119.
10.1093/rheumatology/kev318.
Preview |
Text
Denton_IVIG_revision.pdf - Accepted Version Download (168kB) | Preview |
Abstract
Objective. IVIG is known to confer significant benefit in rheumatologic conditions, including inflammatory myopathy. This study aimed to assess the efficacy of IVIG across different aspects of internal organ involvement in refractory active SSc, particularly the gastrointestinal (GI) system. / Methods. SSc patients with overlap polymyositis who remained active and unresponsive to conventional disease-modifying agents and who subsequently received IVIG were identified. GI symptoms were assessed using validated questionnaires. The Medical Research Council Sum Score for muscle strength and modified Rodnan skin score (mRSS) were assessed. Serial measurements were undertaken at baseline prior to the first IVIG treatment and post-treatment in the most recent assessment. / Results. Fifteen SSc patients were consecutively recruited into this observational study. The mean duration of IVIG treatment was 2.3 years, with treatment frequency ranging from every 6 weeks to 4 months. Compared with baseline, there was a significant reduction in gastro-oesophageal reflux frequency and intensity mean scores (P = 0.006 and P = 0.013, respectively). Significant improvement in the Gastrointestinal Tract (GIT) 2.0 score from a baseline mean score of 1.07 (s.d. 0.67) to 0.60 (0.46) (P = 0.002) was observed. There was regression in the markers of muscle disease with a reduction in the mean (s.d.) Medical Research Council sum score and the median creatine kinase level (P = 0.001 and P = 0.025, respectively). Significant amelioration of the mean basal modified Rodnan skin score from 21.5 (s.d. 13.8) to 10 (10.6) (P = 0.005) was observed. / Conclusion. IVIG may be a helpful adjunctive therapy in the amelioration of some key clinical aspects in refractory SSc. Sustained benefit from IVIG suggests a specific immunomodulatory effect on those with established SSc GI complications.
| Type: | Article |
|---|---|
| Title: | Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/rheumatology/kev318 |
| Publisher version: | http://dx.doi.org/10.1093/rheumatology/kev318 |
| Language: | English |
| Additional information: | This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record, Raja, J; Nihtyanova, SI; Murray, CD; Denton, CP; Ong, VH; (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology, 55 (1) pp. 115-119, is available online at: http://dx.doi.org/10.1093/rheumatology/kev318. |
| Keywords: | systemic sclerosis, intravenous immunoglobulin, gastrointestinal manifestation, myositis, refractory |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1479090 |
Archive Staff Only
 |
View Item |
